Please login to the form below

Not currently logged in

Merck’s Keytruda picks up third approval for NSCLC in China

New indication as a first-line treatment in combination with chemotherapy


Merck & Co/MSD’s blockbuster anti-PD-1 therapy Keytruda has scored its third first-line approval for the treatment of non-small cell lung cancer (NSCLC) in China in less than a year. 

The additional indication approval from China’s National Medical Products Administration (NMPA) was based on the results from the phase 3 KEYNOTE-407 study.

The study investigated Keytruda (pembrolizumab) in combination with chemotherapy treatments carboplatin and paclitaxel for the first-line treatment of metastatic squamous NSCLC.

The data from this trial showed that the Keytruda combination demonstrated a statistically significant improvement in overall survival and progression-free survival in NSCLC patients, compared to treatment with chemotherapy alone.

The Keytruda-chemotherapy combination reduced the risk of death by 36% compared to chemotherapy alone, and reduced the risk of disease progression or death by 44% compared to treatment with chemotherapy.

“This approval expands our current lung cancer indications in China to include KEYTRUDA in combination with chemotherapy in patients with squamous cell carcinoma, a particularly difficult-to-treat type of lung cancer,” said Jonathan Cheng, vice president, oncology clinical research, Merck Research Laboratories.

Lung cancer is the leading cause of cancer death in China, with more than 787,000 new cases of lung cancer diagnosed in China each year and more than 631,000 deaths caused by the disease.

NSCLC is the most common type of lung cancer, accounting for 85% of all new cases.

“In less than one year, we have received three first-line approvals for Keytruda, in combination with chemotherapy or as monotherapy, in non-small cell lung cancer,” said Joseph Romanelli, President of MSD in China.

“Keytruda, in combination with chemotherapy or as monotherapy, has demonstrated a significant survival benefit versus chemotherapy and we will continue to work closely with the external stakeholders to bring this important treatment option to patients,” he added.

As well as winning approvals in NSCLC, Keytruda also became the first drug in the class to be approved in China for advanced melanoma.

However, it was not the first PD-1 inhibitor to get a green light in the country – Bristol-Myers Squibb won that prize for Opdivo (nivolumab) in NSCLC back in 2018.

The increasing size and growth of China’s pharma market has made it a significant target for many big Western pharma companies, but the approval of new cancer immunotherapies has in the country has been slow.

The likes of BMS, Merck and AstraZeneca are quickly making up for lost time, however, with filings for approval in the largest therapy areas – such as NSCLC – now a regular occurrence.

Article by
Lucy Parsons

27th November 2019

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company Events and Exhibition Stands is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....